Use of acetylcholinesterase inhibitors to manage dementia-related behavioral and psychological symptoms in people with Alzheimer disease may reduce the need for psychotropic medications.
Results from a study evaluating the safety and efficacy of suvorexant (Merck) for the treatment of insomnia in patients with mild to moderate Alzheimer disease dementia were presented at the AAN meeting.
Avanir announced data from the phase 3 clinical program that evaluated AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) for the treatment of moderate-to-severe agitation in patients with Alzheimer dementia.
Biogen and Eisai have made the decision to discontinue two phase 3 trials evaluating aducanumab for the treatment of mild cognitive impairment due to Alzheimer disease (AD) and mild AD dementia.
Having affected first-degree, second-degree, or third-degree relatives is associated with an increased risk for Alzheimer disease.
Researchers analyzed the cross-sectional relationships among regional tau, β-amyloid, and cortical thickness and neuropsychological function in Alzheimer disease.
Differences in Alzheimer biomarkers suggest possible race-dependent biological mechanisms that contribute to expression of disease.
Per study data published in the Journal of Clinical Psychiatry, investigators hypothesized that the correlation between higher Frailty Index scores and increased caregiver burden was partially mediated by increased behavioral and psychological symptoms of dementia.
The use of trazodone in older patients with dementia was associated with similar levels of risk for falls and fractures as atypical antipsychotics.
The burden of Alzheimer disease and related dementias (ADRD) is expected to increase to 3.3% in the United States by 2060.